-- Scott Roberts
MONDAY, Jan. 24 (HealthDay News) -- Viibryd (vilazodone
hydrochloride) tablets have been approved by the U.S. Food and Drug
Administration to treat symptoms of major depressive disorder (MDD)
MDD is diagnosed when daily life is affected by symptoms that
may include depressed mood, loss of interest in once-pleasurable
activities, significant changes in weight or appetite, and changes
in sleep habits. Episodes can occur only once or multiple times
throughout a person's lifetime, the FDA said in a news release.
In clinical testing, adverse reactions to Viibryd included
diarrhea, nausea, vomiting and insomnia.
Viibryd and all other approved antidepressants have a boxed
label warning that they have shown an increased risk of suicidal
thinking among children, teens, and young adults aged 18 to 24, the
Viibryd is manufactured by PGXHealth, based in New Haven,
National Institute of Mental Health has more about
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Publishing. All rights reserved.